CURRENT STATUS AND FUTURE OF TRANSPLANTATION OF PRIMARY FETAL DOPAMINE NEURONS IN PARKINSON'S DISEASE Abstract 1-01 The Lund Experience O. Lindvall Section of Restorative Neurology, Wallenberg Neuroscience Center, University Hospital, Lund, Sweden Our open-label clinical studies with intrastriatal transplants of embryonic mesencephalic tissue in 18 patients with Parkinson’s disease (PD) provide proof-of-principle for the cell replacement strategy in this disorder. The grafted dopaminergic neurons can survive, restore regulated dopamine (DA) release and movement-related frontal cortical activation, and give rise to significant symptomatic relief. In the most successful cases, patients have been able to withdraw L-dopa treatment after transplantation and resume an independent life. However, there are currently several problems linked to the use of primary embryonic tissue: First, the lack of sufficient amounts of tissue for transplantation in more than a few patients. Second, the variability of the functional outcome with some patients showing major improvement whereas others exhibit only modest, if any, clinical benefit. This lack of consistent efficacy is probably due to several factors such as variation in the viability and composition of the graft tissue, but also issues related to patient selection and optimal graft placement. Third, although most likely not due to overgrowth of the dopaminergic graft, it is clear that dyskinesias can occur after implantation of human embryonic tissue. We must understand the underlying mechanisms and be able to avoid this adverse effect. To conclude, neural transplantation is still at an experimental stage in PD. Several scientific problems must be addressed before this approach should be further tested in patients.
Cell Transplantation publishes original, peer-reviewed research and review articles on the subject of cell transplantation and its application to human diseases. To ensure high-quality contributions from all areas of transplantation, separate section editors and editorial boards have been established. Articles deal with a wide range of topics including physiological, medical, preclinical, tissue engineering, and device-oriented aspects of transplantation of nervous system, endocrine, growth factor-secreting, bone marrow, epithelial, endothelial, and genetically engineered cells, among others. Basic clinical studies and immunological research papers are also featured. To provide complete coverage of this revolutionary field, Cell Transplantation will report on relevant technological advances, and ethical and regulatory considerations of cell transplants. Cell Transplantation is now an Open Access journal starting with volume 18 in 2009, and therefore there will be an inexpensive publication charge, which is dependent on the number of pages, in addition to the charge for color figures. This will allow work to be disseminated to a wider audience and also entitle the corresponding author to a free PDF, as well as prepublication of an unedited version of the manuscript.